Table 1.
Clinicopathological data of the studied CRC patients (N=113)
| Clinicopathological data | Number (%) |
|---|---|
| Gender | |
| Male Female |
57(50.4) 56(49.6) |
| Age | |
| Mean± SD Range Median |
52.04±14.36 21 - 86 52 |
| Family History | |
| Present Absent |
11(9.7) 102(90.3) |
| Clinical presentation | |
| Bleeding per rectum Abdominal pain Constipation Constipation+ Bleeding per rectum |
44(38.9) 29(25.7) 39(34.5) 1(0.9) |
| Initial presentation of Intestinal obstruction | |
| Present Absent |
30(26.5) 83(73.5) |
| Site of tumor | |
| RT. Colon LT. colon Rectum |
48(42.5) 41(36.3) 24(21.2) |
| Mean± SD Range Median |
6.22±3.55 1.8 – 20 6 |
| Gross morphology | |
| Fungating mass Ulcer Infiltrating |
48(42.1) 34(30.1) 31(27.4) |
| Gross perforation | |
| Present Absent |
8(7.1) 105(92.9) |
| T Stage | |
| T1 T2 T3 T4 |
3(2.7) 23(20.4) 64(56.6) 23(20.4) |
| N Stage | |
| N0 N1 N2 |
60(53.1) 33(29.2) 20(17.7) |
| M Stage | |
| M0 M1 |
90(79.6) 23(20.4) |
| AJCC stage grouping | |
| I II III IV |
21(18.6) 37(32.7) 32(28.3) 23(20.4) |
| Histopathological type | |
| Conventional adenocarcinoma Mucinous Mixed adenocarcinoma and mucinous carcinoma |
81(71.1) 12(10.9) 20(17.7) |
| Grading | |
| High Low |
29(25.7) 84(74.3) |
| Association with adenoma in bowel Present Absent |
16(14.2) 97(85.8) |
| Lymphovascular invasion Positive Negative |
17(15.0) 96(85.0) |
| Perineural invasion Positive Negative |
12(10.6) 101(89.4) |
| Necrosis Present Absent |
23(20.4) 90(79.6) |
| Margins Free Involved |
110(97.3) 3(2.7) |
| Mitotic count Mean± SD Range Median |
6.75±5.44 1 – 17 7 |
| Tumor budding number Mean± SD Range |
4.56±4.69 0 – 14 |
| Tumor budding score High Intermediate Low |
31(27.4) 22(19.5) 60(53.1) |
| Tumor border configuration Infiltrating Pushing |
52(46.0) 61(54.0) |
| CEA Unknown Normal High |
41(36.3) 56(49.6) 16(14.2) |
| CA19.9 Unknown Normal High |
41(36.3) 58(51.3) 14(12.4) |
| KRAS Mutant Unknown |
3(2.7) 110(97.3) |
| MSI Unknown Stable High |
111(98.2) 1(0.9) 1(0.9) |
| No. of Chemotherapy lines 0 1 2 |
29(25.7) 54(47.8) 19(25.7) |
| Type of Chemotherapy Oxalobased Oxalo-based+folfiri Oxalo-based+xeloda |
53(46.9 19(16.8) 10(8.8) |
| Treatment Palliative (surgery+CT+palliative RT) Surgery Surgery+CT Surgery+CT+avastin+maintenance xeloda,avastin+CRT Surgery+CT+CRT Surgery+CT+maintenance xeloda |
1(0.9) 31(27.4) 59(62.2) 1(0.9) 19(16.8) 2(1.8) |
| Time of surgery After CT After CRT After CT+CRT Unfront |
2(1.8) 17(15.0) 1(0.9) 93(82.3) |
| No. of metastasis 1 2 3 4 5 >5 |
3(2.7) 9(8.0) 3(2.7) 3(2.7) 2(1.8) 10(8.8) |
| Local treatment of OMD CRT RFA RT Surgery |
1(0.9) 2(1.8) 1(0.9) 7(6.2) |
| Response CR PD PR DS |
85(75.2) 20(17.7) 3(2.7) 5(4.4) |
| Synchronous or metachronous metastasis Synchronous Metachronous |
23(76.7) 7(23.3) |
| Progression status Present Absent |
20(17.7) (82.3) |
| PFS Mean± SD Range |
17.44±8 7- 44 |
| Survival status Alive Dead |
82(72.8) 31(27.4) |
| Overall survival Mean± SD Range |
20.44±8.41 7 – 44 |